NECTAR LIFESCIENCES Latest Share Price (NECLIFE)
TODAY IN ONE LINE
NECLIFE dropped 3.6% on above-average volume (10515.8x avg), lagging Nifty's -0.3% move, with no exchange filing today, suggesting a market-driven move.
With a market cap of ₹228.06 Cr., it trades at a P/E of N/A. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
NECTAR LIFESCIENCES flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●Positive Free Cash FlowFCF has been positive for 3 consecutive years
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Poor Price MomentumStock underperformed, dropping 40.2% over 1Y
Latest NECTAR LIFESCIENCES News
What changed recently?
Recent events, corporate actions, and announcements.
NECTAR LIFESCIENCES valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for NECTAR LIFESCIENCES, framed against the sector median so the premium or discount is obvious at a glance.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
NECTAR LIFESCIENCES technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for NECTAR LIFESCIENCES — derived from the latest tape, not yesterday's close.
NECTAR LIFESCIENCES last traded at ₹11.5 with an intraday range of ₹11.41–₹12.18 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹11.50| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 13.52 | +2.02 | +17.59% |
| R3 | 12.75 | +1.25 | +10.90% |
| R2 | 12.47 | +0.97 | +8.41% |
| R1 | 11.98 | +0.48 | +4.20% |
| PIVOT | 11.70 | 0.20 | 1.71% |
| CURRENT | 11.50 | — | — |
| S1 | 11.21 | -0.29 | -2.49% |
| S2 | 10.93 | -0.57 | -4.99% |
| S3 | 10.44 | -1.06 | -9.19% |
| S4 | 9.67 | -1.83 | -15.88% |
NECLIFE is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹11.9–₹12.18
Trading Below opening range, showing Bearishness
NECTAR LIFESCIENCES financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for NECTAR LIFESCIENCES — consolidated or standalone — with margins, YoY growth and key ratios inline.
NECTAR LIFESCIENCES reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹228.06 Cr. and reported EPS of ₹-0.68.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 1,673 | — ▼ 100.0% |
| Sales Growth YoY %Derived | -0.74% | -100.00% |
| Other Income | 2 | 9 ▲ 391.3% |
| Total Income | 1,675 | 9 ▼ 99.4% |
| 1,368 | — ▼ 100.0% | |
| Gross ProfitDerived | 305 | — |
| Gross Margin %Derived | 18.23% | — |
| 332 | 61 ▼ 81.7% | |
| EBITDA (Operating Profit)Derived | -26 | — |
| OPM %Derived | -1.58% | — |
| 137 | 36 ▼ 73.4% | |
| Profit Before Tax (PBT) | -162 | -88 ▲ 45.6% |
| -48 | -31 ▲ 36.2% | |
| Effective Tax %Derived | 29.62% | 34.74% |
| Profit/Loss from Discontinued Ops | — | -236 |
| Total Profit for Period | -114 | -57 ▲ 49.6% |
| Net Profit (Owner's PAT)Derived | -114 | -57 ▲ 49.6% |
| Net Profit Margin %Derived | -6.79% | — |
| PAT Growth YoY %Derived | -2,376.07% | 49.55% |
| Earnings Per Share (EPS ₹) | -5.07 | -15.08 ▼ 197.4% |
| Diluted Shares Outstanding (Cr) | 22 | 19 ▼ 13.4% |
| Other Comprehensive Income (Net of Tax) | 1 | 0 ▼ 85.3% |
| Total Expenses (incl. D&A & Interest) | 1,836 | 97 ▼ 94.7% |
| Material Cost % of RevenueDerived | 74.76% | — |
| Employee Cost % of RevenueDerived | 5.77% | — |
| Other Cost % of RevenueDerived | 14.05% | — |
| Interest Coverage (x)Derived | -1.19x | — |
| Period | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 1,901 | 2,783 ▲ 46.4% | 2,367 ▼ 15.0% | 1,544 ▼ 34.7% | 1,669 ▲ 8.1% | 1,525 ▼ 8.6% | 1,686 ▲ 10.6% | 1,673 ▼ 0.7% | — ▼ 100.0% | |
| Sales Growth YoY %Derived | — | 46.39% | -14.96% | -34.75% | 8.06% | -8.64% | 10.56% | -0.74% | -100.00% | |
| Other Income | 6 | 6 ▲ 6.6% | 4 ▼ 32.7% | 3 ▼ 32.0% | 11 ▲ 314.9% | 42 ▲ 274.0% | 13 ▼ 69.2% | 2 ▼ 85.5% | 9 ▲ 391.3% | |
| Total Income | 1,907 | 2,789 ▲ 46.3% | 2,371 ▼ 15.0% | 1,547 ▼ 34.7% | 1,680 ▲ 8.6% | 1,567 ▼ 6.7% | 1,699 ▲ 8.4% | 1,675 ▼ 1.4% | 9 ▼ 99.4% | |
1,367 | 2,218 ▲ 62.2% | 1,859 ▼ 16.2% | 1,157 ▼ 37.7% | 1,223 ▲ 5.7% | 1,159 ▼ 5.2% | 1,202 ▲ 3.7% | 1,368 ▲ 13.8% | — ▼ 100.0% | ||
| Gross ProfitDerived | 534 | 565 ▲ 5.8% | 508 ▼ 10.1% | 387 ▼ 23.8% | 446 ▲ 15.1% | 365 ▼ 18.0% | 483 ▲ 32.3% | 305 ▼ 36.9% | — | |
| Gross Margin %Derived | 28.09% | 20.31% | 21.47% | 25.08% | 26.71% | 23.96% | 28.68% | 18.23% | — | |
297 | 301 ▲ 1.2% | 288 ▼ 4.3% | 277 ▼ 3.8% | 287 ▲ 3.6% | 311 ▲ 8.4% | 330 ▲ 6.1% | 332 ▲ 0.4% | 61 ▼ 81.7% | ||
| EBITDA (Operating Profit)Derived | 237 | 264 ▲ 11.7% | 220 ▼ 16.7% | 110 ▼ 50.0% | 159 ▲ 44.0% | 54 ▼ 66.0% | 153 ▲ 183.8% | -26 ▼ 117.3% | — | |
| OPM %Derived | 12.45% | 9.50% | 9.30% | 7.13% | 9.50% | 3.54% | 9.08% | -1.58% | — | |
180 | 211 ▲ 17.8% | 187 ▼ 11.7% | 147 ▼ 21.2% | 136 ▼ 7.6% | 139 ▲ 2.1% | 148 ▲ 6.7% | 137 ▼ 7.4% | 36 ▼ 73.4% | ||
| Profit Before Tax (PBT) | 63 | 59 ▼ 6.2% | 37 ▼ 36.3% | -85 ▼ 326.2% | 34 ▲ 140.2% | -42 ▼ 224.5% | 18 ▲ 143.1% | -162 ▼ 984.2% | -88 ▲ 45.6% | |
10 | 11 ▲ 7.8% | 6 ▼ 49.4% | -12 ▼ 302.4% | 9 ▲ 178.5% | -18 ▼ 301.9% | 13 ▲ 172.8% | -48 ▼ 460.5% | -31 ▲ 36.2% | ||
| Effective Tax %Derived | 16.61% | 19.08% | 15.16% | 13.57% | 26.51% | 42.99% | 72.66% | 29.62% | 34.74% | |
| Profit/Loss from Discontinued Ops | — | — | — | — | — | — | — | — | -236 | |
| Total Profit for Period | 52 | 48 ▼ 8.9% | 32 ▼ 33.2% | -73 ▼ 330.5% | 25 ▲ 134.2% | -24 ▼ 196.6% | 5 ▲ 120.7% | -114 ▼ 2376.1% | -57 ▲ 49.6% | |
| Net Profit (Owner's PAT)Derived | 52 | 48 ▼ 8.9% | 32 ▼ 33.2% | -73 ▼ 330.5% | 25 ▲ 134.2% | -24 ▼ 196.6% | 5 ▲ 120.7% | -114 ▼ 2376.1% | -57 ▲ 49.6% | |
| Net Profit Margin %Derived | 2.75% | 1.71% | 1.34% | -4.74% | 1.50% | -1.59% | 0.30% | -6.79% | — | |
| PAT Growth YoY %Derived | — | -8.94% | -33.22% | -330.47% | 134.19% | -196.55% | 120.65% | -2,376.07% | 49.55% | |
| Earnings Per Share (EPS ₹) | 2.33 | 2.12 ▼ 9.0% | 1.42 ▼ 33.0% | -3.27 ▼ 330.3% | 1.12 ▲ 134.3% | -1.08 ▼ 196.4% | 0.22 ▲ 120.4% | -5.07 ▼ 2404.5% | -15.08 ▼ 197.4% | |
| Diluted Shares Outstanding (Cr) | 22 | 22 ▲ 0.0% | 22 ▲ 0.0% | 22 ▲ 0.0% | 22 ▲ 0.0% | 22 ▲ 0.0% | 22 ▲ 0.0% | 22 ▲ 0.0% | 19 ▼ 13.4% | |
| Other Comprehensive Income (Net of Tax) | 1 | 0 ▼ 76.4% | 1 ▲ 110.6% | 0 ▼ 24.6% | 1 ▲ 108.0% | 1 ▲ 5.2% | -0 ▼ 139.1% | 1 ▲ 258.2% | 0 ▼ 85.3% | |
| Total Expenses (incl. D&A & Interest) | 1,844 | 2,730 ▲ 48.1% | 2,333 ▼ 14.5% | 1,632 ▼ 30.1% | 1,646 ▲ 0.9% | 1,609 ▼ 2.2% | 1,680 ▲ 4.4% | 1,836 ▲ 9.3% | 97 ▼ 94.7% | |
| Material Cost % of RevenueDerived | 72.68% | 79.96% | 77.49% | 66.59% | 72.32% | 78.76% | 73.71% | 74.76% | — | |
| Employee Cost % of RevenueDerived | 4.12% | 2.87% | 3.42% | 4.75% | 4.47% | 5.10% | 5.02% | 5.77% | — | |
| Other Cost % of RevenueDerived | 11.52% | 7.94% | 8.75% | 13.19% | 12.74% | 15.32% | 14.57% | 14.05% | — | |
| Interest Coverage (x)Derived | 1.50x | 1.36x | 1.27x | 0.45x | 1.29x | -0.07x | 1.06x | -1.19x | — |
NECTAR LIFESCIENCES segment analysis : revenue and profit mix.
Disclosed business segments at NECTAR LIFESCIENCES with their share of revenue and profit, switchable between consolidated and standalone reporting.
NECTAR LIFESCIENCES discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for NECTAR LIFESCIENCES.
Our AI distills the core fundamental drivers supporting NECTAR LIFESCIENCES, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
NECTAR LIFESCIENCES's investment case rests on 0 positive markers and 1 flagged concerns drawn from the latest reported filings.
What you're getting.
No strengths or opportunities on record.
Key Risks.
SWOT generation temporarily unavailable due to model error. The security token included in the request is invalid.
Flip Conditions.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
NECTAR LIFESCIENCES peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — NECTAR LIFESCIENCES is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
NECTAR LIFESCIENCES chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for NECTAR LIFESCIENCES — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
NECTAR LIFESCIENCES delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for NECTAR LIFESCIENCES over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in NECTAR LIFESCIENCES stood at 79.3% of traded volume, against a 20-day average of 76.1%.
NECTAR LIFESCIENCES announcements: results, concalls, ratings, M&A.
Filings NECTAR LIFESCIENCES sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
NECTAR LIFESCIENCES files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 112 documents below.
General Updates
Please find attached herewith letter sent to the members pursuant to Regulation 36(1)(b)of the SEBI (LODR) Regulations, 2015.
Copy of Newspaper Publication
Please find attached herewith newspaper publication of notice of 31st Annual General Meeting, e-voting, book closure & other information.
Shareholders meeting
Nectar Lifesciences Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 18, 2026
Copy of Newspaper Publication
Please find attached herewith newspaper publication of notice to the shareholders regarding 31st AGM of the Company to be held on Friday, September…
Copy of Newspaper Publication
Nectar Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication
NECTAR LIFESCIENCES dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue NECTAR LIFESCIENCES has declared, sequenced by announce and record date.
NECTAR LIFESCIENCES corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
NECTAR LIFESCIENCES insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in NECTAR LIFESCIENCES as reported to SEBI — buying and selling signals from the people who know the business best.
NECTAR LIFESCIENCES insider activity below tracks 1 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| RAMAN GOYAL | Insider | 19 Dec 2024 | buy | +4.00 L | ₹1.77 Cr. | ₹44.37 |
About NECTAR LIFESCIENCES: business, sector, key facts.
What NECTAR LIFESCIENCES does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
NECTAR LIFESCIENCES operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: NECLIFE, BSE: 532649.
Nectar Lifesciences Limited, operating under the name NECLIFE, is a pharmaceutical company based in Chandigarh, India, with both domestic and international operations. Their core business revolves around the manufacturing and sale of pharmaceutical products, focusing heavily on the Cephalosporin class of antibiotics.
A significant portion of NECLIFE's business involves the production of Active Pharmaceutical Ingredients (APIs) and intermediates. These APIs form the building blocks of many finished medications and include a wide range of cephalosporins such as cefixime, cefuroxime axetil (in both amorphous and crystalline forms), cefotaxime sodium, ceftriaxone sodium, and several others. This demonstrates a specialization in the production of key components for a specific antibiotic family.
Beyond API manufacturing, NECLIFE offers contract manufacturing services for finished dosage forms. This means the company produces finished medications for other pharmaceutical companies, expanding their business model beyond just providing raw materials. The finished dosage forms they manufacture include tablets, capsules, dry powder oral suspensions, granules, and injectables, primarily focusing on cephalosporin-based medications based on their API production strengths.
In addition to their core pharmaceutical business, NECLIFE also produces and sells menthol and pearl capsules, indicating some diversification into other areas of the pharmaceutical and possibly supplement markets. This suggests a strategy to broaden their product portfolio and potentially target different market segments.
Established in 1995, NECLIFE has built a considerable presence in the pharmaceutical industry, demonstrating expertise in both API production and finished dosage form manufacturing. Their focus on cephalosporin antibiotics, coupled with contract manufacturing services, suggests a strategic approach to leverage their manufacturing capabilities and cater to the demands of a broad customer base.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AAREY DRUGS & PHARM (AAREYDRUGS) Share PricePeer
- AARTI DRUGS (AARTIDRUGS) Share PricePeer
- AARTI PHARMALABS (AARTIPHARM) Share PricePeer
- AJANTA PHARMA (AJANTPHARM) Share PricePeer
- AKUMS DRUGS AND PHARMA L (AKUMS) Share PricePeer
- Top Losers TodayScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about NECTAR LIFESCIENCES (NECLIFE).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of NECTAR LIFESCIENCES (NECLIFE)?
The current share price of NECTAR LIFESCIENCES (NECLIFE) is ₹11.50. Today, the stock has declined by ₹0.43 (3.6%), trading in a range of ₹11.41 to ₹12.18. The stock opened at ₹11.93 with a trading volume of 1,10,885 shares.
02Is NECTAR LIFESCIENCES stock a good investment for long-term?
NECTAR LIFESCIENCES can be considered for long-term investment based on several factors. The company has a market capitalization of ₹228.06 Cr., P/E ratio of 0, ROE of -9.85%, and ROCE of -8.89%. The dividend yield stands at 0%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of NECTAR LIFESCIENCES stock?
The 52-week high price of NECTAR LIFESCIENCES (NECLIFE) is ₹21.40, while the 52-week low is ₹9.30. Currently trading at ₹11.50, the stock is 23.66% above its 52-week low and 46.26% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy NECTAR LIFESCIENCES stock at the current price?
Whether to buy NECTAR LIFESCIENCES stock at ₹11.50 depends on multiple factors. The stock is currently trading with a P/E ratio of 0 and P/B ratio of 0.4. Today's performance shows a loss of 3.6%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of NECTAR LIFESCIENCES and when is the next dividend?
NECTAR LIFESCIENCES offers a dividend yield of 0%, which means for every ₹100 invested at the current price of ₹11.50, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of NECTAR LIFESCIENCES?
NECTAR LIFESCIENCES's key financial metrics include: P/E Ratio: 0, P/B Ratio: 0.4, ROE: -9.85%, ROCE: -8.89%, Dividend Yield: 0%, EPS: ₹-0.68, Book Value: ₹29.97, and Debt-to-Equity: 0. The company's market cap stands at ₹228.06 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is NECTAR LIFESCIENCES stock performing today in the market?
NECTAR LIFESCIENCES stock opened at ₹11.93 and is currently trading at ₹11.50, showing a decline of ₹0.43 (3.6%). The intraday high is ₹12.18 and low is ₹11.41. The trading volume stands at 1,10,885 shares, indicating moderate market participation today.
08What is the P/E ratio of NECTAR LIFESCIENCES and what does it indicate?
NECTAR LIFESCIENCES has a Price-to-Earnings (P/E) ratio of 0, which means investors are willing to pay 0.00 for every ₹1 of earnings. With an EPS of ₹-0.68, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about NECTAR LIFESCIENCES (NECLIFE) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.